ProNAi – $158 Million IPO

San Diego – August 7, 2015 – Cooley advised the underwriters on ProNAi Therapeutics, Inc.'s $158.4 million initial public offering. ProNAi is a clinical-stage oncology company pioneering a novel class of therapeutics based on its proprietary DNA interference (DNAi) technology platform. Shares of the company's stock now trade on The NASDAQ Global Market under the symbol "DNAI."

Jefferies LLC and BofA Merrill Lynch acted as joint book-running managers for the offering. Wedbush PacGrow and SunTrust Robinson Humphrey acted as co-managers.

The Cooley corporate securities team representing the underwriters included partners Charlie Kim, David Peinsipp and Div Gupta and associates Kristin VanderPas, Dani Nazemian and Susan Walker.

About Cooley LLP

High-growth and established companies, investors and investment banks focused on technology and life sciences partner with Cooley on transformative deals and high-stakes matters, where innovation meets the law.

Cooley has 850 lawyers across 12 offices in the United States, China and Europe.

Related Contacts
Susan Cooper Philpot Partner, San Francisco
David Peinsipp Partner, San Francisco
Charlie Kim Partner, San Diego
Natasha Leskovsek Partner, Washington, DC
Laura McDaniels Special Counsel, Palo Alto
Kevin King Partner, Washington, DC
Bill Christiansen Partner, Seattle
Karen Tsai Associate, Washington, DC
Kristin VanderPas Partner, San Francisco
Phil Mitchell Partner, New York
Dani Nazemian Associate, San Diego
Div Gupta Partner, New York
Aaron Nudelman Associate, Seattle